Evidence map›Paper›PMID 29061967›Full record

ArticleNature communications2017

High grade serous ovarian carcinomas originate in the fallopian tube.

S Intidhar Labidi-Galy, Eniko Papp, Dorothy Hallberg, Noushin Niknafs, Vilmos Adleff, Michael Noe, Rohit Bhattacharya, Marian Novak, Siân Jones, Jillian Phallen and 16 more

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 446 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
446citing papers in PubMed, 5 pooled it
75.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03860805 naactive not recruitingnot on this mapstarted 2019, after this paper: background citation

SALpingectomy for STERilization (SALSTER); a Randomized Trial

TypeinterventionalSponsorGöteborg UniversityRan2019 to 2050Enrolled900ConditionsSterilization Tubal, Salpingectomy, Laparoscopy, Ovarian ReserveArmsLaparoscopic tubal ligation, Laparoscopic bilateral salpingectomy
NCT04812938 unknown statusnot on this mapstarted 2021, after this paper: background citation

Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test

TypeobservationalSponsorAzienda Ospedaliera San Giovanni BattistaRan2021 to 2022Enrolled190ConditionsOvarian CancerArmsPatients with Ovarian cancer and pap test available
3 · Its place in the literature

Who cites it

446 citing papers in PubMed, 5 syntheses or guidelines pooled it, 732 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.The Cochrane database of systematic reviews · 2023
    Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

386 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 3 countries.

S Intidhar Labidi-GalyDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02215, USA.
Eniko PappSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Dorothy HallbergSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Noushin NiknafsSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Vilmos AdleffSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Michael NoeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Rohit BhattacharyaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Marian NovakDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02215, USA.
Siân JonesPersonal Genome Diagnostics, Baltimore, MD, 21224, USA.
Jillian PhallenSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Carolyn A HrubanSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Michelle S HirschDepartment of Pathology, Brigham and Women's hospital and Harvard Medical School, Boston, MA, 02115, USA.
Douglas I LinDepartment of Pathology, Brigham and Women's hospital and Harvard Medical School, Boston, MA, 02115, USA.
Lauren SchwartzDepartment of Pathology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
Cecile L MaireDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02215, USA.
Jean-Christophe TilleDivision of Clinical Pathology, Faculty of Medicine, Geneva University Hospital, 1205, Geneva, Switzerland.
Michaela BowdenDepartment of Pathology, Brigham and Women's hospital and Harvard Medical School, Boston, MA, 02115, USA.
Ayse AyhanDepartment of Pathology, Seirei Mikatahara Hospital, Hamamatsu, 433-8558, Japan.ORCID http://orcid.org/0000-0003-0136-4271
Laura D WoodSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Robert B ScharpfSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Robert KurmanSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Tian-Li WangSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Ie-Ming ShihSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Rachel KarchinSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Ronny DrapkinDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02215, USA. rdrapkin@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-6912-6977
Victor E VelculescuSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. velculescu@jhmi.edu.ORCID http://orcid.org/0000-0003-1195-438X
Johns Hopkins University · USBrigham and Women's Hospital · USHuman Genome Sciences (United States) · USHarvard University · USHiroshima University · JPUniversity Hospital of Geneva · CHUniversity of Pennsylvania · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Vaccinating against IGFBP-2 to prevent ovarian cancer relapseP50CA083636 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DRESCHER, CHARLES, URBAN, NICOLE DENISE · 1999 to 2015
$35.1M
Predoctoral Training Program in Human GeneticsT32GM007814 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 1985 to 2021
$10.6M
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker DiscoveryU01CA152990 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BIRRER, MICHAEL, SKATES, STEVEN J · 2010 to 2021
$8.9M
Large-Scale Genetic Analyses of Human CancerR01CA121113 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANAGNOSTOU, VALSAMO, VELCULESCU, VICTOR E. · 2006 to 2022
$4.3M
Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancerU01CA200469 · NCI · JOHNS HOPKINS UNIVERSITY · PI SHIH, IE-MING, ZHANG, ZHEN · 2016 to 2021
$2.9M
NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA083636NCI NIH HHS R01 CA121113NCI NIH HHS U01 CA152990NCI NIH HHS U01 CA200469NIGMS NIH HHS T32 GM007814
6 · The paper itself

Abstract

High-grade serous ovarian carcinoma (HGSOC) is the most frequent type of ovarian cancer and has a poor outcome. It has been proposed that fallopian tube cancers may be precursors of HGSOC but evolutionary evidence for this hypothesis has been limited. Here, we perform whole-exome sequence and copy number analyses of laser capture microdissected fallopian tube lesions (p53 signatures, serous tubal intraepithelial carcinomas (STICs), and fallopian tube carcinomas), ovarian cancers, and metastases from nine patients. The majority of tumor-specific alterations in ovarian cancers were present in STICs, including those affecting TP53, BRCA1, BRCA2 or PTEN. Evolutionary analyses reveal that p53 signatures and STICs are precursors of ovarian carcinoma and identify a window of 7 years between development of a STIC and initiation of ovarian carcinoma, with metastases following rapidly thereafter. Our results provide insights into the etiology of ovarian cancer and have implications for prevention, early detection and therapeutic intervention of this disease.

Indexed as

AllelesCystadenocarcinoma, SerousDNA Copy Number VariationsFallopian Tube NeoplasmsFallopian TubesFemaleHumansImmunohistochemistryLaser Capture MicrodissectionNeoplasms, Cystic, Mucinous, and SerousOvarian Neoplasms

Identifiers

PMID29061967
PMCPMC5653668
OpenAlexW2767122952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.